Dexmedetomidine Inhibits Ferroptosis Through the Akt/Gsk3β/Nrf2 Axis and Alleviates Adriamycin -Induced Cardiotoxicity

Published: Jan. 1, 2025

Language: Английский

---

Brusatol inhibits malignant phenotypes and lipid metabolism of osteosarcoma cells by regulating PI3K/AKT and MAPK pathways

Phytomedicine, Journal Year: 2025, Volume and Issue: 139, P. 156464 - 156464

Published: Feb. 12, 2025

Language: Английский

---

Piperlongumine overcomes osimertinib resistance via governing ubiquitination-modulated Sp1 turnover

JCI Insight, Journal Year: 2025, Volume and Issue: 10(6)

Published: March 23, 2025

Non-small cell lung cancer (NSCLC) is a common cause of cancer-related deaths worldwide, and its incidence has been increasing in recent years. While targeted therapies like osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor, have brought about notable improvements patient outcomes for advanced NSCLC, the challenge acquired drug resistance persists. Here, we found that cellular mesenchymal-epithelial transition (c-Met) was highly expressed osimertinib-resistant cells, depletion c-Met markedly inhibited cells ex vivo vivo, suggesting potential target to address osimertinib resistance. Through screening process using natural product compound library, identified piperlongumine as potent inhibitor overcome Furthermore, combined treatment exhibited robust antitumor effects resistant partially restoring their sensitivity osimertinib. Additionally, discovered could enhance interaction between E3 ligase RNF4 Sp1, inhibit phosphorylation Sp1 at Thr739, facilitate ubiquitination degradation lead destabilization, trigger intrinsic apoptosis cells. In summary, our study sheds light on overcoming resistance, offering new strategies perspectives clinical management drug-resistant NSCLC.

Language: Английский

---

Dexmedetomidine inhibits ferroptosis through the Akt/GSK3β/Nrf2 axis and alleviates adriamycin-induced cardiotoxicity

Life Sciences, Journal Year: 2025, Volume and Issue: 371, P. 123609 - 123609

Published: April 5, 2025

Language: Английский

---

NRF2 Antioxidant Cellular System as a Therapeutic Target for Enhancing Cancer Radiosensitivity

Meditsinskaya Fizika, Journal Year: 2025, Volume and Issue: 1, P. 94 - 109

Published: April 14, 2025

Contents 1. Introduction 2. Molecular mechanisms of the cellular NRF2 antioxidant system function 3. Activation in cancer cells under oxidative stress caused by ionizing irradiation 4. as a factor radioresistance 5. cell target targeted therapy to increase radiosensitivity 6. Conclusion

Language: Английский

---

Self-assembled nanoplatform-mediated co-delivery of brusatol to sensitize sorafenib for hepatocellular carcinoma treatment

RSC Advances, Journal Year: 2025, Volume and Issue: 15(15), P. 11675 - 11687

Published: Jan. 1, 2025

We developed a glutathione (GSH) responsive nanoplatform for the co-delivery of sorafenib (Sor) and brusatol (Bru). This enhanced Bru’s efficacy increased Sor’s sensitivity. innovative approach effectiveness in hepatocellular carcinoma (HCC) treatment.

Language: Английский

---

Role of Natural Compounds Modulating Heme Catabolic Pathway in Gut, Liver, Cardiovascular, and Brain Diseases

Biomolecules, Journal Year: 2024, Volume and Issue: 14(1), P. 63 - 63

Published: Jan. 2, 2024

The crucial physiological process of heme breakdown yields biliverdin (BV) and bilirubin (BR) as byproducts. BV, BR, the enzymes involved in their production (the “yellow players—YP”) are increasingly documented endogenous modulators human health. Mildly elevated serum concentration has been correlated with a reduced risk multiple chronic pro-oxidant pro-inflammatory diseases, especially elderly. BR BV per se have demonstrated to protect against neurodegenerative which oxygenase (HMOX), main enzyme pigments, is almost always altered. HMOX upregulation interpreted tentative defense ongoing pathologic mechanisms. With demonstration that cells possess YP, propensity be modulated, broad spectrum activity on signaling pathways, YP assumed role an adjustable system can promote health adults. Based that, there effort induce therapeutic option, natural compounds attractive alternative goal, possibly requiring only minimal changes life style. We review most recent evidence potential targeting context common condition adult elderly life.

Language: Английский

---

A Descriptive Review of the Antioxidant Effects and Mechanisms of Action of Berberine and Silymarin

Molecules, Journal Year: 2024, Volume and Issue: 29(19), P. 4576 - 4576

Published: Sept. 26, 2024

Oxidative stress is a key factor in the development of chronic diseases such as type 2 diabetes, cardiovascular diseases, and liver disorders. Antioxidant therapies that target oxidative damage show significant promise preventing treating these conditions. Berberine, an alkaloid derived from various plants Berberidaceae family, enhances cellular defenses against through several mechanisms. It activates AMP-activated protein kinase (AMPK) pathway, which reduces mitochondrial reactive oxygen species (ROS) production improves energy metabolism. Furthermore, it boosts activity antioxidant enzymes like superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), thus protecting cells damage. These actions make berberine effective managing conditions, neurodegenerative Silymarin, flavonolignan complex Silybum marianum, particularly for protection. nuclear erythroid 2-related (Nrf2) enhancing enzyme expression stabilizing membranes. Additionally, silymarin formation ROS by chelating metal ions, also diminishes inflammation. This makes beneficial conditions non-alcoholic fatty disease (NAFLD) alcohol-related review aims to highlight distinct mechanisms exert their effects.

Language: Английский

---

Differences in metabolite profiling by cold atmospheric plasma in normal and cancer cells

Journal of Bioenergetics and Biomembranes, Journal Year: 2025, Volume and Issue: unknown

Published: May 5, 2025

Language: Английский

---

Unlocking therapeutic potential of trigonelline through molecular docking as a promising approach for treating diverse neurological disorders

Metabolic Brain Disease, Journal Year: 2023, Volume and Issue: 38(8), P. 2721 - 2733

Published: Oct. 18, 2023

Language: Английский

---